|
TRIM39 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.00859999965886E-07 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
1.626032641866E-12 |
| Stage1-vs-Stage2 |
4.096200E-02 |
| Stage1-vs-Stage3 |
3.244600E-01 |
| Stage1-vs-Stage4 |
1.290000E-01 |
| Stage2-vs-Stage3 |
2.337700E-02 |
| Stage2-vs-Stage4 |
8.295600E-03 |
| Stage3-vs-Stage4 |
5.316000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.58306999999969E-05 |
| Normal-vs-Asian |
5.20727905239937E-12 |
| Caucasian-vs-AfricanAmerican |
1.467350E-01 |
| Caucasian-vs-Asian |
3.437400E-01 |
| AfricanAmerican-vs-Asian |
4.799800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33226762955019E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
7.723200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
4.66293670342566E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.946100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.297000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.529800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.143600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.750410E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.934800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.715400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.46590000005276E-06 |
| Classical-VS-Follicular |
8.927600E-01 |
| Classical-VS-Other |
3.440800E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
8.07840000000004E-05 |
| Tall-VS-Other |
4.258600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.212400E-01 |
| Follicular-VS-Normal |
3.9042991062388E-11 |
| Other-VS-Normal |
7.90870000000332E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
1.006050E-02 |
|
|
